Mithra receives approval in France to market hormone replacement therapy Tibelia
Women's health specialist Mithra has received a marketing authorisation (MA) for the commercialisation of Tibelia in France.
ConclusionThe calibrated PGsd measure provided significant associations with breast cancer comparable to those given by PD. The calibrated PGm performed slightly worse. These findings indicate that the calibration approach developed previously replicates under more general conditions.
Since I stopped taking hormone replacement therapy (HRT) eight years ago, I ’ve been waking up with this peculiar feeling of dread. Should I go back on HRT? I am 66 years old.
(Mayo Clinic) Research led by oncologists Roberto Leon-Ferre, M.D. and Charles Loprinzi, M.D. of Mayo Clinic has found that the drug oxybutynin helps to reduce the frequency and intensity of hot flashes in women who are unable to take hormone replacement therapy, including breast cancer survivors. These findings were presented at the 2018 San Antonio Breast Cancer Symposium.
SAN ANTONIO ? Research led by oncologists Roberto Leon-Ferre, M.D. and Charles Loprinzi, M.D. of Mayo Clinic has found that the drug oxybutynin helps to reduce the frequency and intensity of hot flashes in women who are unable to take hormone replacement therapy, including breast cancer survivors. These findings were presented at the 2018 San [...]
The transition from adolescence to young adulthood in patients with reproductive health care needs such as disorders of sexual development (DSDs) and congenital anomalies is a complex process occurring over several years. The transition process for these patients has is still poorly understood. The patients with DSDs and reproductive issues have specific and unique issues regarding timing of disclosure of diagnosis, genital examinations, gonadectomy, vaginal treatments, surgical procedures hormone replacement therapy, use of long term medication and potential cancer screening.
Authors: Draelos ZD Abstract Facial skin aging is accelerated in postmenopausal females due to decreased collagen, reduced hydration, and loss of skin elasticity constituting the characteristics of estrogen deficient skin (EDS). The presence of estrogen receptors on dermal fibroblasts and epidermal keratinocytes confirms the role of estrogen in skin health. This research examined the efficacy and tolerability of topical methyl estradiolpropanoate (MEP) as an anti-aging cosmeceutical with estrogen like cutaneous effects in postmenopausal women who had never taken hormone replacement therapy (HRT). MEP was applied to...
Menopause is associated with significant symptomatic burden, with approximately two thirds of post menopausal women suffering from vasomotor symptoms, hot flushes and night sweats. The mainstay of treatment for hot flushes continues to be hormone replacement therapy. However, as HRT is contraindicated in some cases, alternative, efficacious treatment options are also required. Hot flushes are thought to arise as a result of significant changes in the neuroendocrine circuitry underpinning the reproductive axis during menopause. This includes reduced circulating ovarian estrogens, hypersecretion of gonadotropins and increase...
We report a case of a rectal-vaginal mass found during a routine pelvic exam in a 60-years-old asymptomatic menopausal woman, with no history of hormone replacement therapy, chronic pelvic pain, infertility or previous gynecological surgery.
No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire. J Obstet Gynaecol Can. 2018 Nov;40(11):1511-1527 Authors: Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L Abstract OBJECTIF: La présente opinion de comité énumère les recommandations pour la prise en charge gynécologique des femmes ayant reçu un diagnostic de syndrome du cancer du sein et de l'ovaire héréditaire (CSOH) en ce qui a trait au dépistage, à la contraception, à la chimioprophylaxie, aux facteurs &...